Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med's stock price has increased by 5% on March 27, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over three consecutive days [1][4]. Company Overview - Hangzhou Tiger Medical Technology Co., Ltd. was established on December 15, 2004, and went public on August 17, 2012. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - The Xinda Australia Fund has a significant holding in Tiger Med, with the Xinda Health China Mixed A Fund (003291) holding 324,900 shares, representing 3.67% of the fund's net value, making it the fourth-largest holding [2][5]. - The fund has generated a floating profit of approximately 825,200 CNY today and 1,052,700 CNY during the three-day increase [2][5]. - The Xinda Health China Mixed A Fund was established on August 18, 2017, with a current size of 409 million CNY. Year-to-date, it has experienced a loss of 7.67%, ranking 8044 out of 8898 in its category, while it has gained 7.13% over the past year, ranking 5616 out of 8181 [2][5].